HitGen Inc. (“HitGen”), a Shanghai Stock Exchange STAR-listed company (ticker code 688222.SH), today announced that the company has successfully completed the multiple-target drug discovery research projects with UPPTHERA, a Korean pharmaceutical company aiming for new drug development employing “Protein Degradation Technology”.
April 6, 2022
· 2 min read